Revvity (RVTY) AI Stock Analysis

• Market Cap: $10.99B
• Dividend Yield: 0.3%
• Average Volume (3M): 1.53M
• Price to Earnings (P/E): 36.9
• Beta (1Y): 0.67
• Revenue Growth: 1.62%
• EPS Growth: 78.53%
• Country: US
• Employees: 11,000
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.01
• Shares Outstanding: 117,869,660
• 10 Day Avg. Volume: 1,225,184
• 30 Day Avg. Volume: 1,525,673
• PEG Ratio: 6.26
• Price to Book (P/B): 1.48
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 21.30
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $118.08
• Price Target Upside: 26.61% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 14

Revvity's overall stock score is primarily driven by its stable financial position and successful management of cash flows. However, downward technical trends and a high valuation relative to peers moderate the score. The earnings call provided a positive outlook with effective mitigation strategies for existing challenges, supporting a balanced but cautious investment perspective.

Positive Factors

Impressive Tariff Management

RVTY's ability to offset a large tariff-related headwind in a short amount of time is both impressive and surprising.

Resilience in Market Turbulence

Revvity, Inc.'s transformed portfolio is expected to be resilient through ongoing market turbulence.

Tariff Mitigation

Revvity is proactive in addressing tariff headwinds, placing it ahead in mitigation measures compared to larger peers.

Negative Factors

Growth Challenges

Expectations for Life Sci Instruments have been lowered, which is causing a headwind to the company's top-line growth.

Spending Concerns

Concerns persist over spending on early-stage research, which could impact future growth.

Revvity Business Overview & Revenue Model

Company Description

Revvity (RVTY) is a dynamic company operating in the technology sector, specializing in innovative software solutions. The company focuses on developing cutting-edge platforms that enhance business productivity and efficiency. With a commitment to leveraging the latest advancements in technology, Revvity offers a range of products designed to meet the evolving needs of its diverse clientele.

How the Company Makes Money

Revvity generates revenue primarily through the sale of its software solutions, which are marketed to businesses seeking to streamline their operations and improve efficiency. The company offers subscription-based services, providing a steady stream of recurring income. Additionally, Revvity may engage in strategic partnerships with other technology firms to expand its market reach and enhance product offerings, further contributing to its revenue growth. The company's focus on innovation ensures it remains competitive in the fast-paced technology sector, attracting a broad customer base.

Revvity Financial Statement Overview

Summary

Revvity demonstrates a stable financial footing with strong cash flow management and a solid balance sheet. However, the income statement reveals challenges in maintaining revenue growth and profitability margins, which could impact future financial performance. The company is well-positioned financially but must focus on reversing revenue declines to sustain long-term growth.

Income Statement

Revvity's income statement shows a mixed performance. The revenue has seen a slight increase in the TTM, but a significant decline when compared to previous years, indicating a concerning trend in revenue growth. The gross profit margin is strong at 56.3% for TTM, but net profit margin has decreased to 11.2%, indicating rising costs or inefficiencies. EBIT and EBITDA margins have also seen a decline from previous years. Overall, profitability is under pressure but remains relatively stable for the industry.

Balance Sheet

The balance sheet indicates a solid equity position with a debt-to-equity ratio of 0.44 and an equity ratio of 61.8% for TTM, suggesting financial stability and a conservative capital structure. Return on equity has decreased, reflecting the net income decrease, but remains acceptable at 4.05%. The decrease in total assets over time suggests potential divestments or asset efficiency improvements.

Cash Flow

Cash flow statements show strong free cash flow generation with a positive free cash flow to net income ratio. Operating cash flow to net income ratio is healthy, indicating good cash conversion. Despite a dip in operating and free cash flow in the TTM period, cash flow management appears robust, with a focus on maintaining liquidity and managing capital expenditures efficiently.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.77B	2.76B	2.75B	3.31B	5.07B	3.78B
	Gross Profit
1.56B	1.54B	1.54B	1.99B	2.85B	2.11B
	EBIT
390.65M	346.74M	300.56M	742.70M	1.33B	978.58M
	EBITDA
746.33M	840.25M	713.56M	1.30B	1.73B	1.20B
	Net Income Common Stockholders
309.38M	270.38M	693.09M	569.18M	943.16M	727.89M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.14B	1.16B	1.60B	454.36M	618.32M	402.04M
	Total Assets
12.36B	12.39B	13.56B	14.13B	15.02B	8.01B
	Total Debt
3.33B	3.30B	4.07B	4.56B	5.17B	2.18B
	Net Debt
2.19B	2.14B	3.15B	4.11B	4.55B	1.78B
	Total Liabilities
4.72B	4.73B	5.69B	6.73B	7.89B	4.27B
	Stockholders Equity
7.64B	7.67B	7.87B	7.39B	7.13B	3.74B
Cash Flow		Free Cash Flow
530.05M	541.65M	9.90M	594.18M	1.31B	814.67M
	Operating Cash Flow
614.83M	628.30M	91.27M	679.81M	1.41B	892.18M
	Investing Cash Flow
787.97M	776.16M	1.31B	-132.85M	-4.11B	-504.50M
	Financing Cash Flow
-1.25B	-1.13B	-947.12M	-661.80M	2.94B	-202.87M

Revvity Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 93.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVTY, the sentiment is Negative. The current price of 93.26 is above the 20-day moving average (MA) of 93.21, below the 50-day MA of 99.98, and below the 200-day MA of 113.77, indicating a neutral trend. The MACD of -1.73 indicates Negative momentum. The RSI at 46.94 is Neutral, neither overbought nor oversold. The STOCH value of 26.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RVTY.

Revvity Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DGX	79 Outperform	$19.87B	22.49	13.35%	1.71%	9.38%	6.43%
QGEN	70 Outperform	$9.22B	102.18	2.67%	―	3.31%	―
MEDP	69 Neutral	$8.79B	23.33	65.82%	―	9.87%	32.81%
NTRA	66 Neutral	$20.84B	―	-18.66%	―	51.50%	53.23%
RVTY	65 Neutral	$10.99B	36.87	3.82%	0.30%	1.62%	78.53%
ILMN	53 Neutral	$13.24B	―	-23.82%	―	-3.47%	25.55%
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.83%	16.44%	-0.47%

Revvity Corporate Events

Revvity to Announce Q4 and Full-Year 2024 Results

Revvity announced it will release its fourth quarter and full-year 2024 financial results on January 31, 2025, followed by a conference call led by CEO Prahlad Singh and CFO Max Krakowiak. The company expects fourth-quarter revenue growth of approximately 5% to 6% and anticipates meeting or exceeding its full-year 2024 adjusted earnings per share guidance. Revvity is also set to present at the J.P. Morgan Healthcare Conference, where it will discuss these financial results and future projections, reflecting its strong positioning in the healthcare industry.